Have a feature idea you'd love to see implemented?
Let us know!
DNTH Dianthus Therapeutics Inc
Price (delayed)
$28.1
Market cap
$824.86M
P/E Ratio
6.82
Dividend/share
N/A
EPS
$4.12
Enterprise value
$511.09M
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused
Highlights
The EPS has soared by 151% QoQ and by 110% YoY
The revenue has grown by 28% from the previous quarter and by 9% YoY
Dianthus Therapeutics's quick ratio has surged by 88% YoY but it has decreased by 14% QoQ
Dianthus Therapeutics's net income has shrunk by 57% YoY and by 13% QoQ
DNTH's equity is down by 3.9% QoQ
Key stats
What are the main financial stats of DNTH
Market
Valuations
Earnings
Shares outstanding
29.35M
Market cap
$824.86M
Enterprise value
$511.09M
Price to book (P/B)
2.3
Price to sales (P/S)
233.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
124.11
Revenue
$4.12M
EBIT
-$56.68M
EBITDA
-$57.32M
Free cash flow
-$26.18M
Per share
Balance sheet
Liquidity
EPS
$4.12
Free cash flow per share
-$0.76
Book value per share
$12.21
Revenue per share
$0.12
TBVPS
$10.78
Total assets
$368.96M
Total liabilities
$10.74M
Debt
$407,000
Equity
$358.22M
Working capital
$355.66M
Debt to equity
0
Current ratio
36.46
Quick ratio
36.13
Net debt/EBITDA
5.47
Margins
Efficiency
Dividend
EBITDA margin
-1,391.8%
Gross margin
100%
Net margin
-1,376.4%
Operating margin
-1,669.8%
Return on assets
-20.2%
Return on equity
-21%
Return on invested capital
-150.9%
Return on capital employed
-15.8%
Return on sales
-1,376.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNTH stock price
How has the Dianthus Therapeutics stock price performed over time
Intraday
0.39%
1 week
0.43%
1 month
0.9%
1 year
138.95%
YTD
170.19%
QTD
2.63%
Financial performance
How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$4.12M
Gross profit
$4.12M
Operating income
-$68.76M
Net income
-$56.68M
Gross margin
100%
Net margin
-1,376.4%
The operating income has plunged by 79% YoY and by 18% from the previous quarter
The company's operating margin has shrunk by 65% YoY but it rose by 8% QoQ
Dianthus Therapeutics's net income has shrunk by 57% YoY and by 13% QoQ
DNTH's net margin is down by 45% year-on-year but it is up by 12% since the previous quarter
Growth
What is Dianthus Therapeutics's growth rate over time
Valuation
What is Dianthus Therapeutics stock price valuation
P/E
6.82
P/B
2.3
P/S
233.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
124.11
The EPS has soared by 151% QoQ and by 110% YoY
The stock's price to book (P/B) is 64% more than its last 4 quarters average of 1.4 and 28% more than its 5-year quarterly average of 1.8
DNTH's equity is down by 3.9% QoQ
DNTH's P/S is 91% above its last 4 quarters average of 122.0
The revenue has grown by 28% from the previous quarter and by 9% YoY
Efficiency
How efficient is Dianthus Therapeutics business performance
DNTH's return on invested capital has dropped by 130% year-on-year but it is up by 12% since the previous quarter
The ROE has soared by 66% YoY and by 17% QoQ
The ROS fell by 45% YoY but it rose by 12% QoQ
DNTH's return on assets is up by 43% year-on-year and by 16% since the previous quarter
Dividends
What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNTH.
Financial health
How did Dianthus Therapeutics financials performed over time
The company's total liabilities has surged by 166% YoY and by 10% QoQ
Dianthus Therapeutics's quick ratio has surged by 88% YoY but it has decreased by 14% QoQ
DNTH's debt is 100% smaller than its equity
DNTH's debt is down by 18% since the previous quarter
DNTH's equity is down by 3.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.